Loss of BRM expression is a frequently observed event in poorly differentiated clear cell renal cell carcinoma

Histopathology

Volumn 64, Issue 6, 2014, Pages 847-862

  Xia, Qiu yuan ^a   Rao, Qiu ^a   Cheng, Liang ^b   Shen, Qin ^a   Shi, Shan shan ^a   Li, Li ^a   Liu, Biao ^a   Zhang, Jin ^a   Wang, Yan fen ^a   Shi, Qun li ^a   Wang, Jian dong ^a   Ma, Heng hui ^a   Lu, Zhen feng ^a   Yu, Bo ^a   Zhang, Ru song ^a   Zhou, Xiao jun ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRM SMARCA2; Clear cell carcinoma; Fluorescence in situ hybridization; High grade; Immunohistochemistry; Poorly differentiated; Renal cell carcinoma; Rhabdoid; SWI SNF complex; Von Hippel Lindau

Indexed keywords

BRM PROTEIN; VON HIPPEL LINDAU PROTEIN; SMARCA2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CELL DIFFERENTIATION; CHROMOSOME 3P; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; KIDNEY CARCINOMA; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR GROWTH; VHL GENE; GENETICS; KIDNEY TUMOR; METABOLISM; MUTATION; PATHOLOGY; PROGNOSIS;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 84898057938     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12334     Document Type: Article

References (61)

1. Cairns P. Renal cell carcinoma. Cancer Biomark. 2010; 9; 461-473.
2. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of renal tumors of adults. Eur. Urol. 2006; 49; 798-805.
3. Rao Q, Chen JY, Wang JD et al. Renal cell carcinoma in children and young adults: clinicopathological, immunohistochemical, and VHL gene analysis of 46 cases with follow-up. Int. J. Surg. Pathol. 2011; 19; 170-179.
4. Rao Q, Liu B, Cheng L et al. Renal cell carcinomas with t(6;11)(p21;q12): a clinicopathologic study emphasizing unusual morphology, novel alpha-tfeb gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am. J. Surg. Pathol. 2012; 36; 1327-1338.
5. Rao Q, Williamson SR, Zhang S et al. Tfe3 break-apart FISH has a higher sensitivity for xp11.2 translocation-associated renal cell carcinoma compared with tfe3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am. J. Surg. Pathol. 2013; 37; 804-815.
6. Wondergem B, Zhang Z, Huang D et al. Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma. Cancer Res. 2012; 72; 4361-4371.
7. Gobbo S, Eble JN, Maclennan GT et al. Renal cell carcinomas with papillary architecture and clear cell components: the utility of immunohistochemical and cytogenetical analyses in differential diagnosis. Am. J. Surg. Pathol. 2008; 32; 1780-1786.
8. Gokden N, Nappi O, Swanson PE et al. Renal cell carcinoma with rhabdoid features. Am. J. Surg. Pathol. 2000; 24; 1329-1338.
9. Shuch B, Bratslavsky G, Shih J et al. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU Int. 2012; 109; 1600-1606.
10. Shuch B, Bratslavsky G, Linehan WM, Srinivasan R. Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist 2012; 17; 46-54.
11. Cheville JC, Lohse CM, Zincke H et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am. J. Surg. Pathol. 2004; 28; 435-441.
12. de Peralta-Venturina M, Moch H, Amin M et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am. J. Surg. Pathol. 2001; 25; 275-284.
13. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene 2009; 28; 1653-1668.
14. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 2011; 11; 481-492.
15. Cheng JX, Tretiakova M, Gong C, Mandal S, Krausz T, Taxy JB. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod. Pathol. 2008; 21; 647-652.
16. Calderaro J, Moroch J, Pierron G et al. SMARCB1/INI1 inactivation in renal medullary carcinoma. Histopathology 2012; 61; 428-435.
17. Liu Q, Galli S, Srinivasan R, Linehan WM, Tsokos M, Merino MJ. Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation. Am. J. Surg. Pathol. 2013; 37; 368-374.
18. Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469; 539-542.
19. Pawlowski R, Muhl SM, Sulser T, Krek W, Moch H, Schraml P. Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int. J. Cancer 2013; 132; E11-E17.
20. Jones S, Wang TL, Shih IeM et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330; 228-231.
21. Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 2010; 363; 1532-1543.
22. Lichner Z, Scorilas A, White NM et al. The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma. Am. J. Pathol. 2013; 182; 1163-1170.
23. Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW, Reisman D. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene 2007; 26; 7058-7066.
24. Delahunt B, McKenney JK, Lohse CM et al. A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis. Am. J. Surg. Pathol. 2013; 37; 311-322.
25. Delahunt B, Sika-Paotonu D, Bethwaite PB et al. Grading of clear cell renal cell carcinoma should be based on nucleolar prominence. Am. J. Surg. Pathol. 2011; 35; 1134-1139.
26. Cuatrecasas M, Catasus L, Palacios J, Prat J. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of brenner tumors and transitional cell carcinomas. Am. J. Surg. Pathol. 2009; 33; 556-567.
27. Rao Q, Cheng L, Xia QY et al. Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (pecomas): a clinicopathological study emphasizing extrarenal pecomas. Histopathology 2013; 62; 642-650.
28. Zhou J, Wang J, Li N et al. Molecularly genetic analysis of von Hippel-Lindau associated central nervous system hemangioblastoma. Pathol. Int. 2010; 60; 452-458.
29. Brunelli M, Eble JN, Zhang S, Martignoni G, Cheng L. Metanephric adenoma lacks the gains of chromosomes 7 and 17 and loss of Y that are typical of papillary renal cell carcinoma and papillary adenoma. Mod. Pathol. 2003; 16; 1060-1063.
30. Brunelli M, Eble JN, Zhang S, Martignoni G, Cheng L. Gains of chromosomes 7, 17, 12, 16, and 20 and loss of Y occur early in the evolution of papillary renal cell neoplasia: a fluorescent in situ hybridization study. Mod. Pathol. 2003; 16; 1053-1059.
31. Brunelli M, Eble JN, Zhang S, Martignoni G, Delahunt B, Cheng L. Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod. Pathol. 2005; 18; 161-169.
32. Gobbo S, Eble JN, Grignon DJ et al. Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am. J. Surg. Pathol. 2008; 32; 1239-1245.
33. Jones TD, Eble JN, Wang M et al. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin. Cancer Res. 2005; 11; 7226-7233.
34. Prayson RA, Castilla EA, Hartke M, Pettay J, Tubbs RR, Barnett GH. Chromosome 1p allelic loss by fluorescence in situ hybridization is not observed in dysembryoplastic neuroepithelial tumors. Am. J. Clin. Pathol. 2002; 118; 512-517.
35. Fallon KB, Palmer CA, Roth KA et al. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-fish analyses in recurrent oligodendrogliomas. J. Neuropathol. Exp. Neurol. 2004; 63; 314-322.
36. Chapman-Fredricks JR, Herrera L, Bracho J et al. Adult renal cell carcinoma with rhabdoid morphology represents a neoplastic dedifferentiation analogous to sarcomatoid carcinoma. Ann. Diagn. Pathol. 2011; 15; 333-337.
37. Kuroiwa K, Kinoshita Y, Shiratsuchi H et al. Renal cell carcinoma with rhabdoid features: an aggressive neoplasm. Histopathology 2002; 41; 538-548.
38. Shannon B, Stan Wisniewski Z, Bentel J, Cohen RJ. Adult rhabdoid renal cell carcinoma. Arch. Pathol. Lab. Med. 2002; 126; 1506-1510.
39. Shannon BA, Cohen RJ. Rhabdoid differentiation of chromophobe renal cell carcinoma. Pathology 2003; 35; 228-230.
40. Lee L, Marsh WL Jr, Wen P. Pathologic quiz case: an 82-year-old woman with a renal mass. Renal cell carcinoma with rhabdoid features. Arch. Pathol. Lab. Med. 2004; 128; 109-110.
41. Leroy X, Zini L, Buob D, Ballereau C, Villers A, Aubert S. Renal cell carcinoma with rhabdoid features: an aggressive neoplasm with overexpression of p53. Arch. Pathol. Lab. Med. 2007; 131; 102-106.
42. Kapoor A, Tutino R, Kanaroglou A, Hotte SJ. Treatment of adult rhabdoid renal cell carcinoma with sorafenib. Can. Urol. Assoc. J. 2008; 2; 631-634.
43. Humphrey PA. Renal cell carcinoma with rhabdoid features. J. Urol. 2011; 186; 675-676.
44. De Vincenzo F, Zucali PA, Ceresoli GL et al. Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma. J. Clin. Oncol. 2011; 29; e529-e531.
45. Kats-Ugurlu G, Maass C, van Herpen C et al. Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-α production. Histopathology 2011; 59; 562-564.
46. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A et al. Bap1 loss defines a new class of renal cell carcinoma. Nat. Genet. 2012; 44; 751-759.
47. Ibragimova I, Maradeo ME, Dulaimi E, Cairns P. Aberrant promoter hypermethylation of pbrm1, bap1, setd2, kdm6a and other chromatin-modifying genes is absent or rare in clear cell rcc. Epigenetics 2013; 8; 486-493.
48. Muchardt C, Yaniv M. Atp-dependent chromatin remodelling: SWI/SNF and co. are on the job. J. Mol. Biol. 1999; 293; 187-198.
49. Hassan AH, Neely KE, Vignali M, Reese JC, Workman JL. Promoter targeting of chromatin-modifying complexes. Front. Biosci. 2001; 6; D1054-D1064.
50. Phelan ML, Sif S, Narlikar GJ, Kingston RE. Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. Mol. Cell 1999; 3; 247-253.
51. Gramling S, Rogers C, Liu G, Reisman D. Pharmacologic reversal of epigenetic silencing of the anticancer protein brm: a novel targeted treatment strategy. Oncogene 2011; 30; 3289-3294.
52. Moore LE, Jaeger E, Nickerson ML et al. Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation. Oncogenesis 2012; 1; e14.
53. La Rochelle J, Klatte T, Dastane A et al. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer 2010; 116; 4696-4702.
54. Klatte T, Rao PN, de Martino M et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J. Clin. Oncol. 2009; 27; 746-753.
55. Brunelli M, Eccher A, Gobbo S et al. Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod. Pathol. 2008; 21; 1-6.
56. Presti JC Jr, Wilhelm M, Reuter V, Russo P, Motzer R, Waldman F. Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J. Urol. 2002; 167; 1464-1468.
57. Ma X, Yang K, Lindblad P, Egevad L, Hemminki K. VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium. Oncogene 2001; 20; 5393-5400.
58. van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA et al. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from the Netherlands Cohort Study. BMC Cancer 2005; 5; 57.
59. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012; 366; 883-892.
60. Fox DT, Duronio RJ. Endoreplication and polyploidy: insights into development and disease. Development 2013; 140; 3-12.
61. Pan CC, Sung MT, Huang HY, Yeh KT. High chromosomal copy number alterations in xp11 translocation renal cell carcinomas detected by array comparative genomic hybridization are associated with aggressive behavior. Am. J. Surg. Pathol. 2013; 37; 1116-1119.